Clinical trial

Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors

NCT07524322

StatusRECRUITING

Study typeINTERVENTIONAL

Start date2026-06-01

PhasePHASE1

Study timeline

Study start (estimated)2026-06-01Date precision: month

Registry last updated2026-07-22

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Breast Cancerunresolved

Ovarian Cancerunresolved

Endometrial Cancerunresolved

PIK3CA Mutationunresolved

HER2- Negative Breast Cancerunresolved

Advanced Breast Cancerunresolved

Unresectable Solid Tumorunresolved

Hormone Receptor Positive Tumorunresolved

Cervical Cancerunresolved

Interventions

Sponsors & collaborators

Regor Pharmaceuticals Inc.lead sponsor

Mapped research locations

HoustonTexas, United States2 Los AngelesCalifornia, United States1 San AntonioTexas, United States1 FairfaxVirginia, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT07524322 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.